Skip to main content
. Author manuscript; available in PMC: 2023 Mar 15.
Published in final edited form as: Circulation. 2022 Jan 19;145(11):819–828. doi: 10.1161/CIRCULATIONAHA.121.056276

Table 2.

Subgroup Analyses - Cost, Life Expectancy, and Cost Effectiveness*

Subgroup CABG Medical Therapy Difference Incremental Cost-Effectiveness Ratio Probability of Cost-Effectiveness by Willingness-to-Pay threshold ($/QALY)
$50,000 $100,000 $150,000
0–2 Vessel Disease
 Total Costs, USD 137,652
(103,640 – 177,631)		 78,226
(61,406 – 97,974)		 59,426
(30,694 – 95,906)		 - - - -
 QALYs 6.38
(5.37 – 7.54)		 5.82
(5.25 – 6.49)		 0.56
(−0.25 – 1.42)		 $106,752 per QALY 0.08 0.46 0.65
3 Vessel Disease
 Total Costs, USD 143,567
(107,360 – 188,165)		 69,810
(54,622 – 87,386)		 73,756
(42,741 – 113,276)		 - - - -
 QALYs 6.80
(5.52 – 8.24)		 5.02
(4.49 – 5.64)		 1.78
(0.72 – 2.98)		 $41,476 per QALY 0.71 0.98 1.00
LVEF ≤ 28%
 Total Costs 135,441
(101,502 – 176,159)		 67,916
(53,112 – 84,421)		 67,495
(38,187 – 104,831)		 - - - -
 QALYs 6.15
(5.20 – 7.28)		 4.84
(4.38 – 5.35)		 1.31
(0.54 – 2.21)		 $51,370 per QALY 0.47 0.95 0.99
LVEF > 28%
 Total Costs 146,356
(109,993 – 190,063)		 83,420
(64,780 – 104,702)		 62,936
(32,209 – 100,657)		 - - - -
 QALYs 7.04
(5.72 – 8.52)		 6.35
(5.69 – 7.15)		 0.69
(−0.38 – 1.80)		 $90,687 per QALY 0.14 0.55 0.71
*

Reported costs and benefits are discounted at 3%, except for sensitivity analyses that use a 0% and 5% discount rate. Costs, LYs, and QALYs are represented by means and 95% confidence intervals.

Abbreviations: CABG – coronary artery bypass grafting, LVEF – left ventricular ejection fraction, LY – life years, QALY – quality-adjusted life years, USD – US dollars.